Invitae
Corporate brand
UnclaimedInvitae was a United States biotechnology and medical diagnostics company focused on genetic testing and genomic information services.
Last updated August 26, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Invitae was a biotechnology and clinical diagnostics company that built its business around genetic testing, genomic analysis, and the use of genetic information in medical decision-making. The company was created in 2010 as a subsidiary of Genomic Health and became an independent company through a 2012 spin-off. Its corporate identity was associated with an effort to make genetic testing more broadly available across inherited disease, cancer, reproductive health, and other clinical areas. Invitae's business developed through a combination of in-house testing services and acquisitions. In 2017, it acquired Good Start Genetics, a company associated with reproductive genetic testing, and CombiMatrix, a clinical laboratory specializing in cytogenomic testing. CombiMatrix brought capabilities in areas including prenatal and pediatric diagnostics, miscarriage analysis, pre-implantation genetic screening, chromosomal microarray analysis, fluorescence in situ hybridization, and karyotyping. The acquisition expanded Invitae's reach beyond hereditary disease testing and into reproductive and developmental diagnostics. The company pursued a rapid expansion strategy during the late 2010s and early 2020s. In 2020, Invitae announced an agreement to acquire ArcherDX for approximately $1.4 billion. ArcherDX added molecular diagnostics and cancer-testing capabilities, particularly in areas involving next-generation sequencing and liquid-biopsy-related technologies. In 2021, Invitae announced the acquisition of Ciitizen, a healthcare artificial-intelligence company, for approximately $325 million. Ciitizen's technology was intended to organize and interpret clinical and genomic records, particularly for patients with cancer and rare diseases. Invitae's wider offering included genetic tests for hereditary cancer risk, inherited disorders, reproductive health, pediatric conditions, cardiovascular disease, and other clinical indications. It also provided testing and interpretation services to healthcare professionals, patients, researchers, and organizations. The company's positioning emphasized the integration of laboratory testing with digital tools, variant interpretation, clinical records, and information intended to support personalized medicine. The expansion created a broad business footprint but also contributed to substantial financial pressure. Invitae faced rising operating costs, acquisition-related obligations, and challenges in achieving sustainable profitability while attempting to scale genomic testing. In February 2024, reports indicated that the company was preparing for bankruptcy. The New York Stock Exchange subsequently announced that Invitae's shares would be delisted and trading was halted. On February 13, 2024, Invitae filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the District of New Jersey. During the bankruptcy process, Invitae announced an agreement for the acquisition of its business or assets by Labcorp. The transaction marked the end of Invitae as an independent operating company and transferred elements of its testing operations and related assets to a larger laboratory-services organization. Invitae is therefore best understood as a defunct genomic diagnostics brand whose principal legacy lies in expanding the commercial scope of genetic testing and assembling a large portfolio of clinical and genomic information services.
History
Invitae was established in 2010 as a subsidiary of Genomic Health, a company known for genomic testing in medical care. The new company was formed during a period when genetic testing was moving from a specialized laboratory service toward a more widely used component of clinical practice. Invitae's intended role was to provide genetic tests and related information services across a broad range of inherited and acquired conditions. In 2012, Invitae was spun off from Genomic Health and began operating as an independent company. Its development strategy combined laboratory operations, software and information tools, and acquisitions intended to add new clinical areas. Rather than concentrating on a single disease category, Invitae built a portfolio spanning hereditary cancer, inherited disorders, reproductive health, pediatric disease, cardiovascular genetics, and oncology. A significant stage of this expansion came in 2017, when Invitae acquired Good Start Genetics and CombiMatrix. Good Start Genetics strengthened the company's reproductive-health testing activities. CombiMatrix contributed a clinical diagnostic laboratory with experience in prenatal, pediatric, miscarriage, and pre-implantation genetic testing. Its technical capabilities included chromosomal microarray analysis, fluorescence in situ hybridization, and high-resolution karyotyping. CombiMatrix had earlier operated both a research-tools business and a clinical diagnostics business, but by the time of its sale to Invitae its commercial emphasis was on clinical genetic testing. CombiMatrix's own history reflected the development of genomic laboratory technology. The company originated from research into microarrays and DNA analysis, later commercializing array-related tools and establishing a clinical laboratory. Its diagnostic work expanded into oncology, pediatric disorders, and reproductive medicine. The business ultimately focused its resources on clinical diagnostics, with reproductive testing becoming an important growth area before the Invitae transaction. Invitae continued to pursue acquisitions as a way to broaden its capabilities. In 2020, it announced the planned acquisition of ArcherDX for approximately $1.4 billion. ArcherDX brought molecular diagnostic technologies and strengthened Invitae's presence in cancer testing and precision medicine. In 2021, Invitae announced the purchase of Ciitizen for approximately $325 million. Ciitizen's healthcare artificial-intelligence and data-organization capabilities were intended to help structure clinical records and genomic information for research and patient care. The acquisition-led model gave Invitae a wide range of testing and information assets, but it also created a demanding cost structure. The company had to integrate multiple businesses while investing in laboratory capacity, technology, clinical support, and market expansion. Financial pressure became increasingly visible in the early 2020s. In February 2024, media reports said that Invitae was preparing to file for bankruptcy. The New York Stock Exchange then announced that the company's shares would be delisted, and trading was halted. On February 13, 2024, Invitae filed for Chapter 11 bankruptcy protection in New Jersey. The restructuring process included an agreement for Labcorp to acquire the company's business or assets. The transaction ended Invitae's existence as an independent operating company and placed parts of its testing and service platform under a larger laboratory-services group. Invitae's historical importance is tied to its attempt to build a comprehensive, technology-enabled genetic-testing enterprise through a combination of clinical diagnostics, genomic interpretation, and strategic acquisitions.
- 2024
Filed for Chapter 11 bankruptcy
[1]Invitae filed for Chapter 11 bankruptcy protection after its stock was delisted and trading was halted.
- 2024
Reached agreement involving Labcorp
[1]Invitae announced an agreement for Labcorp to acquire its business or assets during the bankruptcy process.
- 2021
Announced Ciitizen acquisition
[1]Invitae announced the acquisition of healthcare AI company Ciitizen for approximately $325 million.
- 2020
Announced ArcherDX acquisition
[1]Invitae announced an approximately $1.4 billion acquisition of ArcherDX to expand molecular diagnostics and oncology testing.
- 2017
Acquired Good Start Genetics and CombiMatrix
[1]The acquisitions expanded Invitae's reproductive, cytogenomic, prenatal, pediatric, and miscarriage-analysis capabilities.
- 2012
Spun off as an independent company
[1]Invitae was separated from Genomic Health and began operating independently.
- 2010
Created as a Genomic Health subsidiary
[1]Invitae was established as a subsidiary of Genomic Health.
Products and positioning
A broad genomic diagnostics and information-services company seeking to make genetic testing more accessible across inherited disease, oncology, reproductive health, and personalized medicine.
Genetic testing
Hereditary cancer testing
Testing intended to identify inherited genetic variants associated with elevated risks of cancer. It formed one of the central clinical areas in Invitae's broad genetic-testing portfolio.
Reproductive genetics
Reproductive health testing
A group of services covering reproductive and prenatal applications, including carrier-related testing, prenatal analysis, miscarriage analysis, and pre-implantation genetic screening capabilities obtained or expanded through acquisitions.
Rare and inherited disease diagnostics
Inherited disease testing
Genetic testing for inherited conditions and rare diseases, intended to support diagnosis, risk assessment, family testing, and clinical management.
Cytogenetic testing
Cytogenomic diagnostics
Cytogenomic services associated with chromosomal microarray analysis, fluorescence in situ hybridization, karyotyping, prenatal diagnostics, pediatric testing, and miscarriage analysis. These capabilities were strengthened by the CombiMatrix acquisition.
Cancer genomics · 2020
Oncology and molecular diagnostics
Molecular and genomic testing for cancer-related applications, including capabilities added through ArcherDX and Invitae's broader precision-medicine strategy.
Healthcare information technology
Genomic information services
Digital and data-oriented services designed to organize genetic results, clinical records, and related information for healthcare professionals, patients, and research use.
Brand decisions
2024
Enter Chapter 11 bankruptcy protectionOtherBackground
Invitae faced financial pressure after a period of rapid expansion and acquisition activity.
Action taken
The company filed for Chapter 11 bankruptcy protection in New Jersey on February 13, 2024.
Aftermath
Invitae's shares were delisted, trading was halted, and the company pursued a transaction involving Labcorp.
2024
Agree to transaction involving LabcorpM&ABackground
The bankruptcy process required a path for continuing or transferring parts of Invitae's business.
Action taken
Invitae announced an agreement for Labcorp to acquire its business or assets.
Aftermath
The agreement marked the transition of Invitae's operations away from an independent corporate structure.
2021
Acquire CiitizenM&ABackground
Invitae aimed to combine genomic testing with structured clinical information and healthcare artificial intelligence.
Action taken
Invitae announced the acquisition of Ciitizen for approximately $325 million.
Aftermath
The transaction added data-organization and clinical-information capabilities to Invitae's platform.
Announced transaction value. $325 million (2021 announcement)
2020
Announce ArcherDX acquisitionM&ABackground
Invitae pursued greater scale in oncology, molecular diagnostics, and precision medicine.
Action taken
Invitae announced an agreement to acquire ArcherDX for approximately $1.4 billion.
Aftermath
ArcherDX's molecular diagnostic capabilities became part of Invitae's expansion into cancer and precision-medicine testing.
Announced transaction value. $1.4 billion (2020 announcement)
2017
Acquire Good Start Genetics and CombiMatrixM&ABackground
Invitae sought to broaden its genetic-testing portfolio beyond its existing hereditary-disease activities.
Action taken
The company acquired Good Start Genetics and CombiMatrix, adding reproductive, cytogenomic, prenatal, pediatric, and miscarriage-analysis capabilities.
Aftermath
The transactions expanded Invitae's clinical scope and laboratory footprint.
Recent events
Reported
Invitae announces full access to Personalized Cancer Monitoring[3]
Invitae announced full access to its Personalized Cancer Monitoring platform, which uses personalized tumor-informed assays to detect minimal or molecular residual disease in patients with solid tumors.
Reported
Invitae appoints Kimber Lockhart to its board[4]
Invitae appointed Kimber Lockhart to its board of directors, effective September 10, 2020.
Reported
Invitae prices public stock offering[5]
Invitae announced the pricing of an underwritten public offering of 17,777,778 shares of common stock at $9.00 per share. The offering was expected to close on or about April 6, 2020, subject to customary closing conditions.
Reported
Invitae announces Invitae Discover research platform[6]
Invitae announced the Invitae Discover clinical research platform, which uses biometric data available through Apple Watch. Its first study will investigate genetic causes of cardiovascular disease.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/invitae · Editorial policy · How profiles are compiled